SAN DIEGO, May 15 /PRNewswire/ -- Tioga Pharmaceuticals announced today that data from a 596 subject Phase 2b study of asimadoline, the company's drug candidate for the treatment of irritable bowel syndrome (IBS), will be featured in a late-breaking oral presentation session at the Digestive Disease Week 2008 Annual Meeting.
Asimadoline is an orally administered small molecule that is a highly selective kappa opioid receptor agonist. Kappa opioid receptors are found in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. Asimadoline was originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga purchased asimadoline from Merck and acquired by assignment all worldwide rights. Asimadoline has been tested in over 1100 subjects and has demonstrated a promising safety profile.
Tioga Pharmaceuticals, Inc. is a pharmaceutical company headquartered in San Diego, CA focused on developing novel treatments for gastrointestinal diseases. Tioga is currently planning Phase 3 development of asimadoline for the treatment of D-IBS and A-IBS and a Phase 2b trial of asimadoline for the treatment of functional dyspepsia. Both disorders represent a large unmet medical need and a substantial market opportunity. For more information, please visit http://www.tiogapharma.com.
CONTACT: David Urso, Chief Business Officer and General Counsel of Tioga
Pharmaceuticals, Inc., +1-858-964-5021, email@example.com; or media,
Cory Tromblee of Porter Novelli Life Sciences, +1-617-897-8294,
firstname.lastname@example.org, for Tioga Pharmaceuticals, Inc.
Web site: http://www.tiogapharma.com/